General Announcement::GPL Announces FDA Acceptance of the Companys First New Drug Application for Ryaltris

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
08-Aug-2018 11:19:19
Status
New
Announcement Sub Title
GPL Announces FDA Acceptance of the Companys First New Drug Application for Ryaltris
Announcement Reference
SG180808OTHRE4WE
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
08/08/2018 17:00:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals Announces FDA Acceptance of the Companys First New Drug Application for Ryaltris for Patients with Seasonal Allergic Rhinitis

Attachments

PR_08082018.pdf
Total size =3222K